Evidence map›Paper›PMID 35229640›Full record

ArticlemBio2022

VPS29 Exerts Opposing Effects on Endocytic Viral Entry.

Daniel Poston, Yiska Weisblum, Alvaro Hobbs, Paul D Bieniasz

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Daniel Poston *Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.ORCID 0000-0001-9900-6717
Yiska Weisblum *Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.ORCID 0000-0002-9249-1745
Alvaro HobbsLaboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.ORCID 0000-0002-2368-3719
Rockefeller University · USCornell University · USHoward Hughes Medical Institute · US

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
RNA Protein interactions in HIV-1 replicationR01AI050111 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2001 to 2021
$7.9M
Immunity and Infectious DiseaseT32AI070084 · NIAID · ROCKEFELLER UNIVERSITY · PI Michel C Nussenzweig · 2008 to 2026
$3.3M
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.F30AI157898 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI POSTON, DANIEL · 2021 to 2024
$191k
Mosquito-malaria interactions in the hemocoelF32AI065075 · NIAID · UNIVERSITY OF MINNESOTA · PI HILLYER, JULIAN F · 2006 to 2007
$67k
Charles H. Revson Foundation (Charles H Revson Foundation Inc) Senior FellowshipHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) F30AI157898HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI65075HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI50111HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R37AI640003HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007739NIAID NIH HHS F30 AI157898NIAID NIH HHS F32 AI065075NIAID NIH HHS R01 AI050111NIAID NIH HHS T32 AI070084NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

Emerging zoonotic viral pathogens threaten global health, and there is an urgent need to discover host and viral determinants influencing infection. We performed a loss-of-function genome-wide CRISPR screen in a human lung cell line using HCoV-OC43, a human betacoronavirus. One candidate gene, VPS29, a component of the retromer complex, was required for infection by HCoV-OC43, SARS-CoV-2, other endemic- and pandemic-threat coronaviruses, as well as ebolavirus. Notably, we observed a heightened requirement for VPS29 by the recently described Omicron variant of SARS-CoV-2 compared to the ancestral variant. However, VPS29 deficiency had no effect on certain other viruses that enter cells via endosomes and had an opposing, enhancing effect on influenza A virus infection. Deficiency in VPS29 or other retromer components caused changes in endosome morphology and acidity and attenuated the activity of endosomal proteases. These changes in endosome properties caused incoming coronavirus, but not influenza virus particles, to become entrapped therein. Overall, these data show how host regulation of endosome characteristics can influence cellular susceptibility to viral infection and identify a host pathway that could serve as a pharmaceutical target for intervention in zoonotic viral diseases.

Indexed as

Coronavirus OC43, HumanCOVID-19Influenza A virusHumansPharmaceutical PreparationsSARS-CoV-2Vesicular Transport ProteinsVirus InternalizationPharmaceutical PreparationsVesicular Transport ProteinsVPS29 protein, humancoronavirusCOVID-19Ebolaebolavirusendosomesgenome-wide CRISPR screeninfluenzainfluenza virusrespiratory virusesretromerSARS-CoV-2traffickingviral entryvirus entryVPS29zoonosis

Identifiers

PMID35229640
PMCPMC8941944
OpenAlexW4214503559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.